Article
Gastroenterology & Hepatology
Yuan-Ji Ma, Ling-Yao Du, Li-Bo Yan, Juan Liao, Xing Cheng, Wu-Wei Xie, Hong Tang
Summary: This study aimed to investigate the long-term prognosis of HCV-infected patients who underwent PR regimen and achieved SVR24. Results showed a low incidence of HCC and progression of liver disease, with cirrhotic patients facing a higher risk of poor prognosis. Recurrence of HCV was rare in responders with SVR24 who had corrected their risky behaviors.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Teresa Broquetas, Paula Herruzo-Pino, Zoe Marino, Dolores Naranjo, Mercedes Vergara, Rosa M. Morillas, Xavier Forns, Jose A. Carrion
Summary: Cirrhosis is present in more than half of HCV-cACLD patients 3 years after SVR, despite the normalization of liver function parameters, serological non-invasive tests, and TE values. The low diagnostic accuracy of non-invasive methods after SVR highlights the necessity of long-term surveillance.
LIVER INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Danilo De Novellis, Valentina Giudice, Vincenzo Ciccone, Paola Erra, Alba De Vita, Francesca Picone, Bianca Serio, Carmine Selleri
Summary: In this article, we report the effective and safe treatment of an old, frail hairy cell leukemia patient with pegylated interferon-alpha-2a as a first-line therapy. After six months of treatment, the patient showed the disappearance of splenomegaly and peripheral hairy cells without any drug-related adverse events.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Ming-Han Hsieh, Tzu-Yu Kao, Ting-Hui Hsieh, Chun-Chi Kao, Cheng-Yuan Peng, Hsueh-Chou Lai, Po-Heng Chuang, Jung-Ta Kao
Summary: SVR lowers the risk of liver histological progression but does not guarantee fibrosis clearance. For SVR cases, those with baseline F >= 2 or without significantly declined follow-up AST levels should be specifically monitored. As for non-SVR cases, those with a higher baseline AST or glucose level should preferentially receive retreatment.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2022)
Article
Immunology
Lorna Leal, Elvira Couto, Sonsoles Sanchez-Palomino, Nuria Climent, Irene Fernandez, Laia Miralles, Yolanda Romero, Tania Gonzalez, Maria Jose Maleno, Blanca Pano, Judit Pich, Carlos Nicolau, Jose Maria Gatell, Montserrat Plana, Felipe Garcia
Summary: The combination of therapeutic vaccine with IFN α-2a was safe and well-tolerated in chronic HIV-1 infected individuals, but had a minimal impact on viral dynamics.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Infectious Diseases
A. Gonzalez-Serna, A. Corma-Gomez, F. Tellez, S. Garcia-Martin, A. Rivero-Juarez, M. Frias, F. J. Vera-Mendez, I De los Santos, D. Merino, L. Morano, A. Imaz, C. Galera, M. Serrano, J. Macias, J. A. Pineda
Summary: The study found that in HIV/HCV coinfected patients, treatment with NNRTI plus 2 NRTI combinations is associated with a higher level of liver stiffness decrease compared to other antiretroviral therapy combinations.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Oncology
Yujin Lim, Sang Eun Yoon, Junhun Cho, Darae Kim, Chul Won Jung
Summary: Erdheim-Chester disease (ECD), a multi-systemic disease with unclear pathogenesis, is treated with pegylated interferon-α (PEG-IFN-α). However, the use of ropegylated-interferon α-2b (ROPEG-IFN-α 2b) for ECD patients has limited data. We report two cases of severe ECD treated with PEG-IFN-α 2a and ROPEG-IFN-α 2b, respectively. Both types of PEG-IFN-α showed excellent disease control, survival outcomes, and manageable toxicities, suggesting the equivalent use of ROPEG-IFN-α 2b for advanced ECD management.
CANCER RESEARCH AND TREATMENT
(2023)
Article
Immunology
Andrea Marques Vieira da Silva, Lucia Elena Alvarado-Arnez, Tamiris Azamor, Leonardo Ribeiro Batista-Silva, Thyago Leal-Calvo, Ohanna Cavalcanti de Lima Bezerra, Marcelo Ribeiro-Alves, Fernanda de Souza Gomes Kehdy, Patricia Cristina da Costa Neves, Camilla Bayma, Jane da Silva, Alessandro Fonseca de Souza, Marcelo Muller, Elisabete Ferreira de Andrade, Ana Carolina Magalhaes Andrade, Eliane Matos dos Santos, Janaina Reis Xavier, Maria De Lourdes De Sousa Maia, Rolando Paez Meireles, Hugo Nodarse Cuni, Guilherme Becker Sander, Paulo Dornelles Picon, Denise C. S. Matos, Milton Ozorio Moraes
Summary: The study found that specific genotypes in the IFNL3/4 gene region can serve as markers for predicting treatment outcomes for patients with chronic hepatitis C (CHC), and observed that certain genotypes may influence immune response and levels of inflammation.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Virology
Ahmed M. Mostafa, Hesham A. Saafan, Ahmed S. Al-Tawashi, Muhannad H. Kasem, Ahmed M. Alaa, Mahmoud M. Eltobgy, Ahmed S. Moubarak, Manar M. Gharib, Mohamed A. Awwad, Hazem M. Omar, Marwa O. El-Derany
Summary: This study aimed to investigate the association between haplotypes in IL-17A receptor rs2275913 and rs3819024 and development of HCC in CHC patients treated with either triple therapy or with dual therapy. The results showed that the presence of G-G haplotype in IL-17A was inversely associated with HCC development in patients receiving triple therapy. High serum AFP levels were directly associated with HCC development in patients receiving triple therapy.
Article
Virology
Kamil Grubczak, Anna Grzeszczuk, Monika Groth, Anna Hryniewicz, Anna Kretowska-Grunwald, Robert Flisiak, Marcin Moniuszko
Summary: HIV/HCV coinfection increases the burden of HCV infection and accelerates disease progression, while regulatory T cells play a crucial role in antiviral immune response during viral treatment.
Article
Ophthalmology
Jongyeop Park, Jisang Han, Tae-Young Chung, Dong Hui Lim, Chul Young Choi
Summary: This study introduces the initial experience of using topical PegIFN-alpha-2a for the treatment of ocular surface squamous neoplasia (OSSN). The retrospective analysis of 8 patients diagnosed with noninvasive OSSN showed that topical PegIFN-alpha-2a was well-tolerated and resulted in reduction and complete resolution of the lesions in all cases.
Article
Gastroenterology & Hepatology
Laura Gragnani, Serena Lorini, Silvia Marri, Umberto Basile, Veronica Santarlasci, Monica Monti, Francesco Madia, Luisa Petraccia, Cristina Stasi, Niccolo Marello, Cecilia Napodano, Francesco Annunziato, Anna Linda Zignego
Summary: Hematological and genetic analyses can be used to predict the clinical response of CV patients to DAAs therapy, aiding in the development of a rational management flowchart.
Article
Multidisciplinary Sciences
Mercedes Marquez-Coello, Ana Arizcorreta, Maria Rodriguez-Pardo, Francisco Illanes-Alvarez, Denisse Marquez, Sara Cuesta-Sancho, Jose-Antonio Giron-Gonzalez
Summary: This study aimed to identify predictive factors for fibrosis regression in HCV-monoinfected and HIV/HCV-coinfected patients after treatment with direct antiviral agents. The results showed that both groups experienced a significant reduction in liver stiffness after achieving sustained virological response, but this improvement was not correlated with changes in serum markers.
SCIENTIFIC REPORTS
(2021)
Review
Immunology
Mamun Al-Mahtab, Sheikh Mohammad Fazle Akbar, Osamu Yoshida, Julio Cesar Aguilar, Gerardo Guillen, Yoichi Hiasa
Summary: An open-level clinical trial has shown that a therapeutic vaccine, NASVAC, containing HBsAg and HBcAg, is effective and safer than Peg-IFN in treating CHB patients. The study also suggests that NASVAC may be particularly beneficial for patients with HBV genotype-D.
Article
Oncology
Taisuke Imamura, Yukiyasu Okamura, Keiichi Ohshima, Katsuhiko Uesaka, Teiichi Sugiura, Takaaki Ito, Yusuke Yamamoto, Ryo Ashida, Katsuhisa Ohgi, Shimpei Otsuka, Sumiko Ohnami, Takeshi Nagashima, Keiichi Hatakeyama, Yuko Kakuda, Takashi Sugino, Kenichi Urakami, Yasuto Akiyama, Ken Yamaguchi
Summary: This study compared the genomic characteristics of hepatocellular carcinoma (HCC) in patients with hepatitis C virus infection who achieved sustained virological response (SVR) or not after surgery using gene expression profiling and whole-exome sequencing. The study found significant differences in mutation rates of several driver genes between HCCs of SVR patients and non-SVR patients, as well as between HCCs of SVR patients treated with direct-acting antivirals (DAA) and interferon (IFN).